This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC), Moderna (MRNA) and Danaher (DHR)

Tipranks - Tipranks - Wed Jun 3, 8:12AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeOne Medicines (ONC), Moderna (MRNA) and Danaher (DHR).

Claim 55% Off TipRanks

BeOne Medicines (ONC)

J.P. Morgan analyst Jessica Fye maintained a Buy rating on BeOne Medicines today. The company’s shares closed last Monday at $279.68, close to its 52-week high of $287.88.

Fye has an average return of 38.4% when recommending BeOne Medicines. ;'>

According to TipRanks.com, Fye is ranked #1199 out of 12287 analysts.

BeOne Medicines has an analyst consensus of Strong Buy, with a price target consensus of $393.49, a 36.8% upside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $436.00 price target.

See today’s best-performing stocks on TipRanks >>

Moderna (MRNA)

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday. The company’s shares closed last Monday at $46.06, close to its 52-week low of $29.25.

According to TipRanks.com, Breen is a 5-star analyst with an average return of 19.7% and a 88.5% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. ;'>

Moderna has an analyst consensus of Hold, with a price target consensus of $44.35, which is a -5.8% downside from current levels. In a report issued on May 22, William Blair also maintained a Hold rating on the stock.

Danaher (DHR)

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Danaher, with a price target of $270.00. The company’s shares closed last Monday at $179.87.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 2.2% and a 51.5% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Danaher has an analyst consensus of Strong Buy, with a price target consensus of $231.53, representing a 26.8% upside. In a report issued on May 27, Citi also resumed coverage with a Buy rating on the stock with a $230.00 price target.

Read More on ONC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).